USA flag logo/image

An Official Website of the United States Government

Development of a Plant-based Vaccine aganist HIV

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65945
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI055271
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Applied Biotechnology Institute
5819 Stallion Ridge College Station, TX 77845
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Development of a Plant-based Vaccine aganist HIV
Agency: HHS
Contract: 1R43AI055271-01
Award Amount: $144,408.00
 

Abstract:

DESCRIPTION (provided by applicant): Plant-based vaccines have now been proven to impart resistance to various viral and bacterial diseases in animals and in humans. These vaccines can be produced in a transgenic plant product such as corn flour. When ingested, the protein subunit induces a mucosal immune response. At the same time, some of the protein epitope induces a serum immune response. Plant-based vaccines, produces in grain, have several advantages including not needing a cold chain or needles. Any HIV immunogens will have excellent stability within the dry corn seed matrix allowing accurate dosing. Extremely inexpensive to produce, plant-based vaccines in corn seed make the ideal delivery system for protein subunit vaccines in areas of the world where a reliable cold chain, needle disposal and top quality medical personnel are issues of great importance. One plant-based vaccine has recently been shown to induce high antibody titers in the colostrums of postpartum female animals. Titers induced by the plant-based vaccine in corn was several-fold higher than using an existing injectable commercial vaccine. Thus, an HIV plant-based vaccine may have promise in controlling HIV transmission from an infected mother to infant through breast milk. We propose to put genes encoding three different HIV immunogens into individual corn lines. Seed material containing each HIV protein would be produced and analyzed for protein expression. High expressing lines will be selected for further development. Animal feeding studies would be conducted during a Phase II grant. Several new HIV gp120-related immunogens have been developed recently and these would make ideal candidates for an edible vaccine. We propose testing a gp120 subtype B strain, a gp140 version of that same strain, and a consensus env sequence recently published by Gaschen et al. (2002, Science 296:2354).

Principal Investigator:

Michael E. Horn
9796901917
MHORN@PRODIGENE.COM

Business Contact:


4096908537
Small Business Information at Submission:

PRODIGENE
PRODIGENE 101 GATEWAY BLVD, STE 100 COLLEGE STATION, TX 77845

EIN/Tax ID: 742764093
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No